Anteris Technologies (ASX:AVR) has announced one-year clinical results demonstrating sustained favourable hemodynamics and excellent safety outcomes for its DurAVR Transcatheter Heart Valve in patients with small aortic annuli, including no valve-related mortality and a very low rate of prosthesis-patient mismatch. …
DurAVR delivers strong one-year results for patients with small aortic annuli
October 29, 2025 Australian Biotech
Latest Video
New Stories
-
Arthritis Australia unveils new grants and identity as research breakthroughs loom
July 16, 2026 - - Latest News -
Organon and Samsung Bioepis expand partnership to broaden biosimilar access in Australia
July 16, 2026 - - Latest News -
A single payer system in which the worst kind of inequity is the only one permitted
July 16, 2026 - - Latest News -
Algorae names Nasdaq pharmaceutical chairman to strengthen board
July 15, 2026 - - Australian Biotech -
Starpharma raises $32 Million to advance dendrimer cancer programs
July 15, 2026 - - Australian Biotech -
Minister recommits to keeping MS medicines on the PBS while awaiting formal advice
July 15, 2026 - - Latest News -
Budget outlook now hangs on disability savings, but what about pharmaceuticals
July 15, 2026 - - Latest News